Cedric Francois - 18 Apr 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Executive Officer, Director
Signature
/s/ David Watson, attorney-in-fact for Cedric Francois
Issuer symbol
APLS
Transactions as of
18 Apr 2023
Net transactions value
-$2,327,220
Form type
4
Filing time
20 Apr 2023, 16:51:14 UTC
Previous filing
05 Apr 2023
Next filing
28 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $80,100 +30,000 +4.7% $2.67* 667,601 18 Apr 2023 Direct F4
transaction APLS Common Stock Sale $2,460,720 -30,000 -4.5% $82.02 637,601 18 Apr 2023 Direct F4, F5
transaction APLS Common Stock Options Exercise $53,400 +20,000 +3.1% $2.67* 657,601 19 Apr 2023 Direct F6
holding APLS Common Stock 634,211 18 Apr 2023 Indirect Owner (The Cedric Francois Irrevocable Trust of 2023) F1
holding APLS Common Stock 300,000 18 Apr 2023 Indirect Owner (The Francois Grossi Trust) F2
holding APLS Common Stock 234,411 18 Apr 2023 Indirect Owner (The Francois-DuBois Educational Trust) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -30,000 -7.5% $0.000000 370,000 18 Apr 2023 Common Stock 30,000 $2.67 Direct F4, F7
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -20,000 -5.4% $0.000000 350,000 19 Apr 2023 Common Stock 20,000 $2.67 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F2 The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
F3 The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
F4 This is a scheduled exercise & sale from 10b5-1 trading plan.
F5 This transaction was executed in multiple trades at prices ranging from $81.29 to $82.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This is a scheduled exercise from 10B5-1 trading plan.
F7 This option was granted on December 5, 2013 and fully vested.